No Data
Zhejiang Jingxin Pharmaceutical Co., Ltd.'s (SZSE:002020) Market Cap up CN¥629m Last Week, Benefiting Both Retail Investors Who Own 48% as Well as Insiders
Zhejiang Jingxin Pharmaceutical (002020.SZ): has repurchased 4.00% of its shares.
On March 21, 2023, Zhejiang Jingxin Pharmaceutical (002020.SZ) announced that by March 21, 2025, the company would repurchase 34.462528 million shares through a dedicated securities account for share repurchase via centralized bidding, accounting for 4.00% of the current total share capital. The highest Fill Price for the purchased shares was 13.93 yuan/share, the lowest Fill Price was 11.86 yuan/share, and the total amount spent was 0.434 billion yuan (excluding transaction fees).
Is Zhejiang Jingxin Pharmaceutical Co., Ltd.'s (SZSE:002020) Recent Stock Performance Tethered To Its Strong Fundamentals?
Zhejiang Jingxin Pharmaceutical (002020.SZ): The revenue from the business in the USA accounts for a small proportion of the company's overall business revenue.
Gelonghui, March 5th丨Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the revenue from its Business in the USA accounts for a small proportion of the company's overall Business revenue, and the additional tariffs imposed by the USA are expected to have no significant impact on the company's performance.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Zhejiang Jingxin Pharmaceutical (002020.SZ) has repurchased a total of 3.01% of its shares, costing 0.32 billion yuan.
Zhejiang Jingxin Pharmaceutical (002020.SZ) announced that as of February 28, 2025, the company will repurchase shares...
Zhejiang Jingxin Pharmaceutical (SZSE:002020) Jumps 5.8% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
